44 results about "Acute cardiac failure" patented technology

Methods of treating acute heart failure in a patient in need thereof. Methods include inserting a therapy delivery device into a pulmonary artery of the patient and applying a therapy signal to autonomic cardiopulmonary fibers surrounding the pulmonary artery. The therapy signal affects heart contractility more than heart rate. Specifically, the application of the therapy signal increases heart contractility and treats the acute heart failure in the patient. The therapy signal can include electrical or chemical modulation.

The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and / or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (e.g., kidney damage or failure, heart valve problems, heart rhythm problems, and / or liver damage); heart failure due to left ventricular dysfunction; heart failure with normal ejection fraction; cardiovascular mortality following myocardial infarction; cardiovascular mortality in patients with left ventricular failure or left ventricular dysfunction; left ventricular failure; left ventricular dysfunction; class II heart failure using the New York Heart Association (NYHA) classification system; class III heart failure using the New York Heart Association (NYHA) classification system; class IV heart failure using the New York Heart Association (NYHA) classification system; LVEF<40% by radionuclide ventriculography; LVEF≤35% by echocardiography or ventricular contrast angiography; and conditions related thereto.

A method for monitoring a health status of a human subject includes the capturing of medical data concerning the health of the subject at defined intervals using a questionnaire. The questionnaire provides a standard script for data capture. Part of the captured data is constrained to a Likert scale while other data is on a visual analog scale. The captured data further includes an assessment by a physician of health symptoms of the subject. The captured data is input into a computer, provided to an algorithm that is configured to assess a risk of acute heart failure. The risk of acute heart failure is computed using the algorithm and the captured data from a plurality of the defined intervals. In one method, the health status of the subject as being either improved or worsening is output to the physician as a function of a value of the computed risk. In another method, a survival function outcome for the subject is predicted using the output of the algorithm.

The invention relates to intermittent administration of an inotropic agent (such as, but not limited to a levosimendan compound) or a pharmaceutically acceptable salt thereof in the treatment of cardiovascular disorders, such as, pulmonary hypertension, myocardial ischemia, acute heart failure, chronic heart failure or acute on chronic heart failure.

The application discloses LTBP2 as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and / or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and / or performing said methods. LTBP2 is also involved in glomerular filtration rate, dyspnea, acute heart failure, left ventricular hypertrophy, cardiac fibrosis, preeclampsia, pregnancy- associated proteinuria.

The application discloses Quiescin Q6 as a new biomarker for acute heart failure. Methods for determining the quantity of Quiescin Q6 in a sample from a subject are described. The quantity of Quiescin Q6 is determined by contacting the sample with one or more binding agents capable of specifically binding to Quiescin Q6.

The present invention discloses a stable hydrochloride olprinone injection which is used for curing acute heart failure. The present invention comprises a drug active ingredient of hydrochloride olprinone, an acid-base buffer system and water-soluble excipient. The present invention is used for curing acute heart failure.

A method and system are presented for use in assessment of at least one cardiac parameter of an individual. An electrodes arrangement is applied to an individual's body, for applying an electrical field to the body and providing an electrical output indicative of a systolic impedance change and of a velocity of said change during a cardiac cycle. Also provided is additional data indicative of at least of the following conditions of the individual: a value of total peripheral resistance (TPR), a value of cardiac index (CI), and existence of the AHF condition. Data corresponding to these condition is analyzed to determine whether the TPR satisfies a first predetermined condition and / or the CI satisfies a predetermined second condition and / or whether the acute heart failure (AHF) condition is identified, to thereby use the data indicative of the measured electrical output and selectively calculate said at least one cardiac parameter based on either the systolic impedance change data or on said data of the velocity of the impedance change.

Methods for detecting angiopoietin-2 (Angpt-2) and / or thrombospondin-2 (Tsp-2) in a sample involve obtaining or having obtained a blood or plasma sample from a subject; and detecting Angpt-2 and Tsp-2 in the sample. Detecting can involve performing an assay to determine whether the sample includes Angpt-2 and / or Tsp-2 or elevated levels of Angpt-2 and / or Tsp-2. Elevated levels are indicative of acute heart failure.